SCIENTIFIC INNOVATIONS
extraordinary, passionate and dedicated
Our team is the fusion of the most advanced biomedical research and a century of real-world medical practice in oncology, and interventional radiology. This unique combination is what drives the innovation engine of Vitalgenics. Our approach to our research and development begins with an exhaustive study of the disease and through the understanding of the cause we design and develop novel technologies that have the potential to revolutionize cancer therapies
OUR SCIENCE – Research and Development

Our mission is to produce disruptive solutions that become safe and effective therapies that are widely accessible to patients as the standard of care for the treatment of specific cancers. This requires our management to prioritize research projects with the greatest potential to impact the lives of the patients we serve. Vitalgenics is always in pursuit to effectively translate our purpose into reality through combining ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for pancreatic cancer and beyond. Through our team’s many decades of the most advanced cancer research and specialized medical practice in hematology, oncology, and interventional radiology we have identified novel, fascinating oncology targets and, importantly, developed key biomarkers to guide the path to the efficacy of our therapeutic discoveries.

Until now Pancreatic Cancer’s exact causes were not well understood

Pancreatic Cancer occurs from the pancreas’ reaction to receiving an excess of outside influences or the encounter of something that disrupts the homeostasis of the pancreas. This disruption of homeostasis entails over 40 continuous biological sequences which we refer to as the pancreatic cancer cascade that leads to tumor formation, tumor growth and metastasis that cannot be effectively resolved by any existing FDA approved pancreatic cancer therapies.

We know that the pancreatic cancer cascade can begin many years before clinical signs appear with risk factors such as long standing diabetes, chronic pancreatitis, smoking, diet, obesity, many other risk factors which lead to the excess or lack of bile or toxicity of the bile which places the pancreas and especially the islets of Langerhans and connective tissue within the pancreas duct at the head of the pancreas on high alert.

The pancreas goes into survival mode and activates the flight or fight response and begins the process of 40 biological sequences that happen in the islets of Langerhans. These islets are the regions of the pancreas that contain its endocrine (hormone-producing) cells, and surrounding connective tissue within the Exocrine pancreatic duct in the head of the pancreas.

After discovering and isolating the cause (target) our team was then able to identify and develop a small-molecule drug compound named Excindogen to stay on target and arrest the 40 biological sequences that lead to tumor formation, tumor growth and tumor metastasis of the pancreas. Our extensive clinical tests show our novel pancreatic cancer therapy, Excindogen represents a revolutionary solution for the potential cure.

EXCINDOGEN is our new novel pancreatic cancer therapy. It is the result of many years of research and development into the study of the causes of Pancreatic Cancer. It has undergone extensive laboratory safety and efficacy testing. Vitalgenics is presently preparing for the FDA's approval to begin human trials. Our clinical results have been nothing less than exciting as they have shown great promise in our goal of stamping out Pancreatic Cancer.
Understanding the Impact of Cancer

Cancer is a collective term used to describe a group of diseases characterized by uncontrolled cell growth and division, with the potential to migrate to and invade distant tissues. Data relating to cancer survival and mortality rates tend be 2-3 years behind the current year due to the time involved in data collection, analysis, compilation and dissemination.

The cost involved in cancer care – the term cancer used henceforth refers collectively to all diseases as – and treatment is a huge financial burden for patient families and healthcare systems globally. In the US, cancer care is cost $150 billion in 2019. Loss in productivity due to premature cancer-related deaths, or from family members taking time off work to care for sick relatives, also has an indirect but significant economic impact.

Many cancers have an unknown aetiology. However mutations in genes that play key roles in tumour suppression such as, BRCA1 and BRCA2, and/or over-expression of proto-oncogenes – normal genes that have the potential to differentiate into cancer-promoting genes i.e. oncogenes – have been linked with the disease. These mutations can be hereditary or result from exposure to external factors such as smoking in lung cancer.

The search for a cure for almost all types of cancer has been ongoing for approximately six decades with billions spent on research. Yet, despite the advances in scientific and medical knowledge, technology, and a deep and better understanding of the human body, a cure is yet to be found. While there has been progress in chemotherapy since the use of nitrogen mustard compounds as chemotherapeutic agents in the 1940s, reducing toxicity of many anti-cancer drugs still remains a huge challenge. Since cancer drugs are designed to target rapidly dividing cancer cells, healthy cells with similar characteristics are often susceptible to these drugs. For an example temporary alopecia (hair loss) is a common side effect of chemotherapy because many anti-cancer drugs impair the mitotic process of actively dividing hair follicles.

Despite the lack of a cure, early screening, better screening methods such as computed tomography (CT,), mammography, positron emission tomography (PET) scanning, medical resonance imaging (MRI), chemotherapy, radiotherapy, and changes in lifestyle behaviors have resulted in an improvement in incidence rates for some cancers. For example, a decline in smoking among men has seen a 51% decline in lung cancer since 1990 with the most rapid progress in recent years. Lung cancer accounts for the top cause of cancer deaths in the developed world, followed by colon, breast, prostate and pancreatic cancer.
In 2020 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the U.S that is more than 1,600 deaths each and every day. To say the least cancer is a major health concern and is the second leading cause of death